文献速递消化系统肿瘤

COMMIT研究:mFOLFOX6/贝伐珠单抗/阿替利珠单抗对比阿替利珠单抗单药一线治疗dMMR转移性结直肠癌

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2026-07-29

COMMIT为三臂前瞻性III期开放标签随机试验,入组一线dMMR/MSI-H转移性结直肠癌患者。因KEYNOTE 177结果,FFX/bev臂在入组20例后关闭,研究继续比较阿替利珠单抗单药与FFX/bev/阿替利珠单抗联合。

要点

  • FFX/bev联合阿替利珠单抗较阿替利珠单抗单药显著延长一线dMMR/MSI-H mCRC的PFS。
  • 联合组客观缓解率86.1%,单药组46%;12个月疾病控制率分别为64.7%和32.4%。
  • 联合组≥3级不良事件52例(单药18例,联合34例),需关注联合治疗毒性。

核心结论

  • 在dMMR/MSI-H转移性结直肠癌一线治疗中,FFX/bev联合阿替利珠单抗较阿替利珠单抗单药显著延长PFS。

研究设计与样本

  • NRG-GI004/SWOG-S1610(COMMIT)为三臂前瞻性III期开放标签随机试验,按1:1:1随机分配一线dMMR/MSI-H mCRC患者。
  • 因KEYNOTE 177结果,FFX/bev臂在入组20例后关闭;研究继续比较阿替利珠单抗单药与FFX/bev/阿替利珠单抗联合,修订样本量为剩余两臂100例(三臂共120例)。
  • 主要终点为意向治疗人群的PFS。

主要发现

  • 两臂中位随访46个月(中位年龄63.3岁;女性47.6%;BRAF V600E突变23.2%)。
  • FFX/bev/阿替利珠单抗组对比阿替利珠单抗组:客观缓解率86.1%对46%,12个月疾病控制率64.7%对32.4%。
  • 任何归因的≥3级不良事件共52例(阿替利珠单抗组18例,联合组34例)。

关键数值与推荐

  • mFOLFOX6方案:奥沙利铂85 mg/m²,亚叶酸钙400 mg/m²,5-FU推注400 mg/m²,46小时持续输注5-FU 2,400 mg/m²。
  • 阿替利珠单抗单药剂量:840 mg静脉注射,每2周一次。
  • PFS主要比较的临界值为0.0152。

临床怎么用

  • 对于一线dMMR/MSI-H转移性结直肠癌,可考虑FFX/bev联合阿替利珠单抗以提高PFS和缓解率。
  • 联合方案≥3级不良事件较多,临床选择时需评估患者耐受性。

局限性

  • FFX/bev臂因KEYNOTE 177结果在入组20例后提前关闭,该臂样本量小。
  • 研究修订样本量后实际入组102例,低于原计划三臂120例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immunotherapy for frontline mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) is effective; however, nearly half of the patients treated with single-agent PD-1 therapy will progress within 12 months. Preclinical studies in CRC and clinical data from other cancers suggest that vascular endothelial growth factor inhibition and chemotherapy can synergize with PD-L1 inhibition. METHODS: The NRG-GI004/SWOG-S1610 (COMMIT) three-arm prospective phase III open-label trial randomly assigned first-line dMMR/MSI-H mCRC patients (1:1:1) to either: mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-FU bolus 400 mg/m², and 46-hour infusional 5-FU 2,400 mg/m²)/bevacizumab (FFX/bev), or atezolizumab (atezo) monotherapy (840 mg IV once every 2 weeks), or the combination of FFX/bev/atezo. The primary end point was progression-free survival (PFS) in the intent-to-treat population. Because of KEYNOTE 177 results, the FFX/bev arm was closed after 20 patients were enrolled. The study continued with atezo alone versus FFX/bev/atezo, with a revised sample size of 100 patients in the two remaining arms (120 patients across all three arms). RESULTS: From November 2017 to March 2025, a total of 102 patients were enrolled in the three arms: FFX/bev: n = 20, atezo: n = 41, and FFX/bev/atezo: n = 41. At a median follow-up of 46 months for the two arms (median age: 63.3 years; 47.6% female; 23.2% BRAF V600E mutated), PFS of FFX/bev/atezo was superior to that of atezo (hazard ratio [HR], 0.439 [95% CI, 0.23 to 0.84]; P = .0103) and below the critical value of 0.0152. The objective response rate was 86.1% versus 46%, and the disease control rate at 12 months was 64.7% versus 32.4% in the FFX/bev/atezo arm compared with the atezo-only arm, respectively. Grade 3 or higher adverse events of any attribution occurred in 52 patients (atezo: 18; combination arm: 34). CONCLUSION: The combination of FFX/bev plus atezo led to significantly longer PFS compared with atezo monotherapy in the first-line treatment of dMMR/MSI-H mCRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rocha Lima CMSP, Yothers G, George TJ, et al. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. J Clin Oncol. 2026. PMID: 42525921. doi:10.1200/JCO-25-03052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。